Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer/Onyx Nexavar Approved For Broad Advanced Kidney Cancer Indication

Executive Summary

FDA's full approval of Bayer/Onyx' kidney cancer therapy Nexavar (sorafenib) covers both refractory and first-line use
Advertisement

Related Content

Torisel’s Positive Effect on Overall Survival Expected To Drive Sales
Torisel’s Positive Effect on Overall Survival Expected To Drive Sales
Stable Cancer Patients Phase I Dosing Could Be Extended If Benefit Shown
Oncology Committee On Brain Tumor Endpoints Planned For Summer – Pazdur
Pfizer Oncologic Sutent Will Have Dosing, Slight Price Advantage Over Nexavar
Oncology, CNS Agents May Dominate 2006 NME Approvals; 2005 Total Is 18
Magnitude Of Effect, Not Survival, Is Key To Approval For Oncologic Nexavar
Magnitude Of Effect, Not Survival, Is Key To Approval For Oncologic Nexavar
Bayer Nexavar Safety Profile Fuels Research In Multiple Cancer Indications
Avastin, Erbitux Costs Invite Price Controls, Former NCI Deputy Says
Advertisement
UsernamePublicRestriction

Register

PS046695

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel